Decoy Therapeutics Inc. lost $129.10 per diluted share in fiscal year 2025. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Decoy Therapeutics Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$129.10
Ticker history: SLRX became
DCOY
(Decoy Therapeutics Inc.) on .
Earlier news and filings retain their original names and dates.
View SLRX history.
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
DCOY EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Decoy Therapeutics Inc. lost $129.10 per diluted share in fiscal year 2025.
Across the 11 fiscal years this page covers, Decoy Therapeutics Inc. (DCOY) diluted earnings per share went from -$2.08 in fiscal year 2015 to -$129.10 in fiscal year 2025.
Decoy Therapeutics Inc. (DCOY) reported -$4.46 in diluted earnings per share in Q2 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Decoy Therapeutics Inc. (DCOY) reported on that line in every period on record.
